Palifosfamide

Drug Profile

Palifosfamide

Alternative Names: IPM-tris; Isophosphamide mustard-tris; Isophosphoramide mustard; Palifosfamide-tris; ZIO-201; ZIO-201-T; Zymafos

Latest Information Update: 09 Dec 2015

Price : $50

At a glance

  • Originator Dekk-Tec
  • Developer ZIOPHARM Oncology
  • Class Antineoplastics; Cyclophosphamides; Oxazines; Small molecules
  • Mechanism of Action Alkylating agents; DNA cross linking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Soft tissue sarcoma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Small cell lung cancer
  • Phase II Breast cancer; Germ cell and embryonal neoplasms; Ovarian cancer; Testicular cancer
  • Phase I Solid tumours
  • Preclinical Haematological malignancies
  • Discontinued Soft tissue sarcoma

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 24 Jul 2015 ZIOPHARM terminates a phase-II clinical trial in Germ cell cancer (Late-stage disease, Second-line therapy or greater) in USA due to slow accural
  • 03 Dec 2014 ZIOPHARM completes a phase III trial in Small cell lung cancer in Hungary and Poland (EudraCT2011-006134-17; NCT01555710)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top